Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 52605-072

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 52605-072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Polygen Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine-10mg-1000count (Memantine 10mg 1000count)

Label for Memantine Hydrochloride Tablets, USP 10 mg film-coated oral tablets. The label states the product contains 1,000 tablets and is manufactured by Polygen Pharmaceuticals Inc., Edgewood, NY. Instructions include storage at 20° to 25°C and keeping drugs out of children's reach. The label bears a barcode, NDC 52605-072-10, and prescription-only designation.*

FDA Label Image

Memantine-10mg-30count (Memantine 10mg 30count)

Memantine Hydrochloride Tablets, USP 10 mg film-coated oral tablets by PolyGen Pharmaceuticals Inc. The label indicates a quantity of 30 tablets, prescription only, with storage instructions and a barcode on the right side.*

FDA Label Image

Memantine-10mg-60count (Memantine 10mg 60count)

Label for Memantine Hydrochloride Tablets, USP 10 mg by Polygen Pharmaceuticals Inc. The film-coated oral tablet package contains 60 tablets. The label includes storage instructions, dosage information, and a barcode, with a prominent display of the 10 mg strength.*

FDA Label Image

Memantine-5mg-1000count (Memantine 5mg 1000count)

Label for Memantine Hydrochloride Tablets, USP, 5 mg strength. The film-coated oral tablets are manufactured by Polygen Pharmaceuticals Inc. and packaged in a container of 1,000 tablets. The label includes storage instructions, a barcode, NDC 52605-071-10, and states the product is for prescription use only (Rx Only).*

FDA Label Image

Memantine-5mg-30count (Memantine 5mg 30count)

Memantine Hydrochloride Tablets, USP 5 mg film-coated tablets label by Polygen Pharmaceuticals Inc. The label includes the dosage strength (5 mg), tablet count (30 tablets), storage instructions (20° to 25°C), NDC 52605-071-13, and directions about dispensing and keeping out of children's reach. It also features a barcode and manufacturer information.*

FDA Label Image

Memantine-5mg-60count (Memantine 5mg 60count)

Label for Memantine Hydrochloride Tablets, USP, 5 mg strength, film-coated tablets. The label indicates the product is prescription-only, with a quantity of 60 tablets. It mentions each tablet contains 5 mg of memantine hydrochloride and includes storage instructions and manufacturer information for Polygen Pharmaceuticals Inc.*

FDA Label Image

Memantine-fig-1 (Memantine Fig 1)

A line graph showing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment. Two lines represent groups: placebo and Memantine hydrochloride (HCl). The graph illustrates a trend of decline in scores over time, with the Memantine HCl group showing less decline compared to placebo. Error bars indicate variability at each time point. Clinical improvement and clinical decline are marked on the y-axis.*

FDA Label Image

Memantine-fig-2 (Memantine Fig 2)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline, comparing Memantine hydrochloride (MEMANTINE HCl) and placebo groups. The x-axis represents ADCS-ADL change, and the y-axis shows cumulative percentage of patients, with distinct curves for Memantine hydrochloride and placebo.*

FDA Label Image

Memantine-fig-3 (Memantine Fig 3)

A line graph showing the mean change from baseline in SIB Score over 28 weeks of treatment comparing Memantine hydrochloride to placebo. The x-axis represents weeks of treatment (0 to 28), and the y-axis represents mean change with SEM. Memantine hydrochloride shows clinical improvement while placebo shows clinical decline, with data points including error bars.*

FDA Label Image

Memantine-fig-4 (Memantine Fig 4)

A cumulative percentage of patients graph comparing Memantine hydrochloride and placebo. The x-axis shows SIB change from baseline, and the y-axis shows cumulative percentage of patients, illustrating a distribution difference between Memantine HCl and placebo groups.*

FDA Label Image

Memantine-fig-5 (Memantine Fig 5)

A line graph comparing the mean change from baseline in ADCS-ADL scores between Placebo/Donepezil and Memantine HCl/Donepezil groups over a 24-week treatment period. The x-axis shows Weeks of Treatment from 0 to 24, and the y-axis shows Mean change ranging from 1 to -4, with markers for Clinical Improvement and Clinical Decline. Memantine HCl/Donepezil group shows a smaller decline compared to Placebo/Donepezil, indicating better maintenance of function over time.*

FDA Label Image

Memantine-fig-6 (Memantine Fig 6)

A cumulative percentage graph showing patient response comparing Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis represents ADCS-ADL change from baseline values, while the y-axis indicates the cumulative percentage of patients. Two curves display trends for each treatment group across the baseline change values.*

FDA Label Image

Memantine-fig-7 (Memantine Fig 7)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment comparing Placebo/Donepezil and Memantine HCl/Donepezil groups. The graph includes error bars and indicates clinical improvement or decline over time on the y-axis and weeks of treatment on the x-axis.*

FDA Label Image

Memantine-fig-8 (Memantine Fig 8)

A cumulative percentage of patients graph depicting SIB (Severe Impairment Battery) change from baseline. It compares two treatment groups: Placebo/Donepezil (square markers) and Memantine HCl/Donepezil (circle markers), showing cumulative patient percentages across a range of SIB score changes.*

FDA Label Image

Structure (Structure)

Chemical structure of Memantine hydrochloride, showing the bicyclic amine with an attached hydrochloride group, methyl groups, and the amine functionality.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.